Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
复制标题
DOI：
10.1634/theoncologist.2011-0205
复制
发表时间：
2012-02-01
期刊：
影响因子：
5.8
通讯作者：
Ueno, Naoto T.
中科院分区：
文献类型：
--
作者：
Cheng, Yee Chung;Takagi, Mariko;Ueno, Naoto T.
目的。单纯接受常规化疗的患者中有 40%-70% 发生卵巢早衰。然而，在接受造血干细胞移植（HSCT）清髓化疗的患者中，发生率更高，为70%-100%。促性腺激素释放激素 (GnRH) 类似物，如连续释放制剂中的亮丙瑞林，可以保护卵巢免受化疗的性腺毒性作用。在非 HSCT 环境中，GnRH 类似物降低了卵巢早衰的风险
Purpose. Premature ovarian failure occurs in 40%-70% of patients who receive conventional chemotherapy alone. However, the incidence is higher, 70%-100%, in patients who undergo myeloablative chemotherapy with hematopoietic stem cell transplantation (HSCT). Gonadotropin-releasing hormone (GnRH) analogs, such as leuprolide, in a continuous-release formulation, may protect the ovaries from the gonadotoxic effects of chemotherapy. In non-HSCT settings, GnRH analogs have reduced the risk for premature ovarian failure to